Answers are grounded in this paper and cite their sources.
Background: Glioblastoma (GBM) remains difficult to treat because of tumour heterogeneity and the limited activity of single-target therapies. Our previous phenotypic drug screen identified JAK2/STAT3 signalling and HSP90-dependent protein homeostasis as pharmacological vulnerabilities. We investigated whether combined JAK2 and HSP90 inhibition could produce broader anti-tumour activity across GBM models. Methods: Multiple JAK2 and HSP90 inhibitors were tested alone and in combination across 2- and 3-dimensional patient-derived GBM stem cell models. Drug interactions were quantified using the zero-interaction potency (ZIP) synergy model. Mechanistic studies included RNA sequencing, flow cytometry, western blotting, immunofluorescence and FUCCI live-cell imaging. Activity was also assessed in cerebral organoid GBM co-cultures, non-malignant human neural and glial cells and orthotopic GBM xenografts. Results: Combined JAK2 and HSP90 inhibition produced synergistic interactions in 12 of the 13 GBM cell lines tested, using multiple structurally distinct inhibitor pairs. Gandotinib and NMS-E973 were selected for further mechanistic studies, where the combination reduced spheroid growth and increased caspase-3 activation and PARP cleavage. Combination treatment was associated with G2/M accumulation, altered mitotic regulation, abnormal chromosome and spindle organisation, and increased gamma-H2AX signalling. Anti-tumour combination activity was maintained in cerebral organoid co-cultures, where tumour burden was reduced as assessed by imaging, histological and luciferase-based measurements, while the drug combination had relatively limited effects on non-malignant human neural and glial cell types tested over the same concentration range. In vivo, combined Pacritinib and NMS-E973 treatment significantly reduced tumour burden in orthotopic G7 xenografts compared with vehicle or either single agent. Conclusions: JAK2/HSP90 co-inhibition produces reproducible anti-tumour activity across heterogeneous GBM models and disrupts cell-cycle and mitotic progression. These findings support further evaluation of this combination strategy in GBM.
No takes yet. Share an insight, caveat, or question.
Furqan et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: